Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT FULCRUM THERAPEUTICS, INC.

Fulcrum Therapeutics, Inc. (NASDAQ: FULC)
Listen to this Section


$3.56
-0.0480 ( -1.33% ) 911.3K

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Market Data


Open $3.56
Previous Close $3.61
Volume 911.3K
Market Cap $240.55M
Day Range $3.56 - $3.73
52 Week Range $2.83 - $15.74
Shares Outstanding 66.63M
Change % -1.33%
Net Change ▼ -0.0480
Insider Ownership -0.86%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2019
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -300,000.00

Date Type Amount Purchased Purchaser
2024-07-08 Sale -150000.00 Sapir Alex
2024-06-18 Sale -30000.00 Dorton Katina
2024-06-18 Sale -30000.00 GERAGHTY JAMES A
2024-06-18 Sale -30000.00 Haviland Kate
2024-06-18 Sale -30000.00 Gould Robert J
2024-06-18 Sale -30000.00 Ezekowitz Alan

SEC Filings


Form Type Description Pages Date
8-k 8K-related 12 Oct 29, 2025
10-q Quarterly Reports 82 Oct 29, 2025
8-k 8K-related 41 Aug 28, 2025
8-k 8K-related 44 Jul 29, 2025
10-q Quarterly Reports 81 Jul 29, 2025
4 Insider transactions 1 Jun 30, 2025
4 Insider transactions 1 Jun 30, 2025
4 Insider transactions 1 Jun 30, 2025
4 Insider transactions 1 Jun 30, 2025
4 Insider transactions 1 Jun 30, 2025

Latest News